>

NanoSyrinx in Parliament

Our Founder and CEO, Joe Healey, was invited by the Parliamentary and Scientific Committee (P&SC – https://www.scienceinparliament.org.uk/) to discuss the future and potential of Synthetic Biology for the UK and for human health.

The UK has a stated (and laudable) ambition to become a “Scientific Superpower”, and Synthetic Biology is intimately tied to that vision. It was a cornerstone of the industrial strategy under previous leadership, and is still very much at the forefront of current science policy thinking.

The panel, was organised by SynBioBeta (the largest synthetic biology community and advocacy group) and Bit.Bio (a UK ‘cell programming’ company) with the P&SC. Whilst the focus of the discussion was particularly what Synthetic Biology could offer for human health, a wide range of topics were covered including synbio for sustainability and Net Zero, as well as a discussion about what the UK entrepreneurship ecosystem needs in order to thrive.

 

The panel was chaired by Stephen Metcalfe MP (South Basildon and East Thurrock), and the speakers included (pictured left to right above):

  • Mark Kotter, CEO of Bit.bio

  • Sara Holland, Patent attorney at Potter Clarkson specialising in synbio IP

  • Stephen Metcalfe MP, chair of the session

  • Fiona Mischel, Director of Human Health content at SynBioBeta

  • Joe Healey, Founder and CEO of NanoSyrinx

Read more news

NanoSyrinx at Number 10

Our CEO Joe Healey was invited to Number 10 this week, to discuss the future of Engineering Biology in the UK as part of a networking and investment breakfast. Synthetic biology or “Engineering Biology” has been highlighted as one of the five key technology areas for the UK’s future economy. Understanding how best to incubate, […]

Read more

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week. Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook […]

Read more
Anthony Johnson, NanoSyrinx NED

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for […]

Read more